Lilly-backed Oyster Therapeutics raises $60m for neurological degraders

​

Oyster Therapeutics has closed a $60m Series A-2 financing round to advance targeted protein degraders for neurodegenerative diseases including Alzheimer’s.

The post Lilly-backed Oyster Therapeutics raises $60m for neurological degraders appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.